IPG Photonics

IPGP · NASDAQ

$72.49+$0.01 (+0.01%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $72.48

IPGP analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $128.32 (+77.0% upside)

Low: $78.78
Now: $72.49
High: $159.60

Upgrades and downgrades

The latest rating actions, newest first

IPGP analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citigroup	Aug 11, 2026	Maintains	Buy	$150.00 → $137.00	44%
Needham	Jul 17, 2026	Maintains	Buy	$110.00 → $120.00	59%
Citigroup	May 6, 2026	Maintains	Buy	$105.00 → $150.00	44%
Stifel	May 6, 2026	Maintains	Buy	$165.00 → $125.00	73%
Needham	May 6, 2026	Upgrade	Hold → Buy	$110.00	59%
Stifel	Feb 13, 2026	Maintains	Buy	$92.00 → $165.00	73%
Raymond James	Feb 13, 2026	Downgrade	Strong Buy → Outperform	$97.00 → $180.00	57%
Roth Capital	Feb 3, 2026	Maintains	Buy	$105.00 → $110.00	30%
Citigroup	Nov 5, 2025	Upgrade	Sell → Buy	$68.00 → $105.00	44%

The case for and against

Updated Oct 14, 2026

Bull case

IPG Photonics is supported by a clearer demand recovery, with Q1 revenue up 17% year over year to $265.5M, book-to-bill firmly above 1.0 for a second straight quarter, and strong bookings plus global PMI trends reinforcing confidence in the 2026 outlook. Its vertically integrated manufacturing model and broadening mix toward higher-growth emerging products—53% to 54% of sales recently—support industry-leading margins, while the planned Lumibird Medical acquisition expands Medical TAM to $2B and lifts Advanced Solutions to 26% of revenue. A fortress balance sheet with $884M of net cash/investments, more than $1B repurchased over three years, and a settlement that removes patent litigation overhang further strengthen the fundamental case.

Bear case

IPG Photonics is facing a deteriorating fundamental backdrop as Q1 revenue of $265.5MM, though up 17% y/y, still showed a 3% sequential decline and only modest upside to consensus, while adjusted gross margin slipped to 37.8% on a 220 bps y/y compression from tariffs and higher product costs. Cash generation also weakened, with cash from operations at $(5)MM and free cash flow at $(22)MM after $16MM of capex, underscoring pressure from annual bonus payments, a high fixed-cost structure, and continued operating investment. Looking ahead, management’s Q2’26 outlook for $260MM-$290MM of revenue, $32MM-$48MM of adjusted EBITDA, and roughly 150 bps of tariff headwinds, combined with economically sensitive industrial demand, rising competition, and China exposure, supports a negative outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.